Fulgent Genetics, Inc.

Fulgent Genetics, Inc. insiders are currently net sellers of FLGT stock, showing bearish sentiment over the past 90 days. Total sales of $34.8M outpace purchases of $9.6M, creating a net outflow of $25.2M.

Fulgent Genetics, Inc. has 14 active insiders who have filed SEC Form 4 transactions in the past 90 days. Ming Hsieh (Executive) leads with 51 transactions totaling $42.0M. Jian Xie (Executive) follows with 107 transactions worth $19.1M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Fulgent Genetics, Inc.'s current score of 22/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Mar 1, 2026, when Hsieh Ming (Executive) disposed of 17,566 shares at $15.33 per share for $269.3K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, FLGT insider trading sentiment is currently bearish with an Alignment Score of 22/100. The negative net flow of $25.2M shows more selling than buying. However, 0% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Fulgent Genetics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At FLGT, we track all Form 4 filings—currently showing 402 transactions from 14 insiders over 90 days.

A 10b5-1 plan allows Fulgent Genetics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At FLGT, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at FLGT appears discretionary, making insider signals more meaningful.

You can monitor Fulgent Genetics, Inc. (FLGT) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 14 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Fulgent Genetics, Inc.'s current score of 22/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $9.6M in purchases versus $34.8M in sales over 90 days, resulting in a net flow of -$25.2M.

SEC Form 4 filings are mandatory reports that Fulgent Genetics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At FLGT, the most common type is "F" with 29 occurrences. The most recent Form 4 was filed on Mar 1, 2026 by Hsieh Ming.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Fulgent Genetics, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at FLGT represents discretionary decisions with more informational value.